All content for Foundation Fighting Blindness is the property of Foundation Fighting Blindness and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
The Foundation funded preclinical studies for the approach and launched Opus.
Eye on the Cure Podcast | Episode 88: Richard Small
Foundation Fighting Blindness
25 minutes 47 seconds
4 months ago
Eye on the Cure Podcast | Episode 88: Richard Small
July 11, 2025. Richard Small, CEO of Neurotech, talks to host Ben Shaberman about ENCELTO™, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel). The therapy is a tiny, implantable capsule, the size of a rice grain, that delivers neurotrophic factors to preserve the patient's retinal cells and vision. The approach was previously developed to treat retinitis pigmentosa and age-related macular degeneration.
Foundation Fighting Blindness
The Foundation funded preclinical studies for the approach and launched Opus.
